GSK Drug Shows Potential Cure for Chronic Hepatitis B
The Spin
Narrative A
Bepirovirsen is a genuine breakthrough for the 240 million people living with chronic hepatitis B — a disease that kills 1.1 million annually and currently demands lifelong treatment. About 1 in 5 patients achieved a functional cure, meaning the immune system controls the virus without any medication. That's a massive leap from the less-than-1% functional cure rate of existing standard care.
Narrative B
Headlines describing a hepatitis B cure may overstate early results because the treatment achieved a functional cure in only a minority of trial participants. Researchers still lack long-term evidence proving patients remain permanently virus-free, while side effects, accessibility and high treatment costs remain concerns. Chronic hepatitis B remains challenging, and broader studies are necessary before celebrating a cure.